National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer
VolitionRx Limited (NYSE AMERICAN: VNRX) presented an abstract at the virtual WCLC lung cancer conference, showcasing Nu.Q™ assays' potential in diagnosing lung cancer. The interim analysis indicates that these assays can reduce unnecessary biopsies by 32% for non-cancerous nodules detected via low-dose computed tomography (LDCT). The study, led by Professor Chen Jin-Shing at National Taiwan University Hospital, involves 1,200 subjects and aims to differentiate between benign nodules and early-stage lung cancers. Results will be published later this year.
- Nu.Q™ assays could reduce unnecessary biopsies by 32%.
- Study involves a substantial cohort of 1,200 subjects, enhancing data reliability.
- Results presented at a prestigious global conference.
- Interim analysis based only on 220 subjects, limiting broader applicability of results.
AUSTIN, Texas, Jan. 28, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has an abstract presented today at the world's largest lung cancer meeting, the WCLC, which is being held virtually this year.
The poster presentation given by Dr. Tung-Ming Tsai of the National Taiwan University Hospital will be featured in the WCLC's Screening and Early Detection session and is entitled "Circulating Nucleosomes in Lung Cancer Diagnosis following Low-Dose Computed Tomography". The key message from the presentation is that, based on an interim analysis of a subset of subjects in an ongoing study, Nu.Q™ assays could help identify non-cancerous nodules following a scan thereby reducing unnecessary biopsies by as much as
Watch a short interview where Chief Scientific Officer, Dr. Jake Micallef discusses the results - https://youtu.be/QbC7eJKw3pQ
Professor Chen Jin-Shing, Principal Investigator of the study said "The results of this interim analysis of a subset of our 1,200-subject study are very promising. Low-Dose Computed tomography (LDCT) is the widely accepted standard for screening of individuals at high risk of lung cancer. However, LDCT has several limitations including poor specificity (high false positives). Results from this study suggest that Nucleosomes and Histone PTMs may discriminate well between non-cancerous benign nodules versus early-stage lung cancer (stages 0, I and II) in non-familial lung cancer history patients. The ability to distinguish between cancerous and non-cancerous nodules could reduce both unnecessary biopsies and the frequency of radiation exposure from repeated LDCT scanning. To accomplish this result through a non-invasive blood test would be an important step forward in lung cancer screening. We look forward to completing the study and publishing our findings in the coming months."
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition said "Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for improved diagnosis. We are hopeful that our Nu.Q™ assays can help identify non-cancerous nodules following a scan. We are delighted that our world-renowned collaborators are presenting this data at such a prestigious conference and share our collaborator's excitement to complete this study and share the findings at scientific conferences later this year."
The abstract can be found here.
To view the poster presentation video please register for the WCLC here
About the Study
A large-scale lung cancer study is being conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of the prestigious National Taiwan University Hospital ("NTUH"). The study will include 1,200 subjects receiving LDCT scans, including 1,000 with lung cancer. Collection commenced in the summer of 2019 and will be completed in May 2021. This interim analysis is based on a subset of 220 subjects.
For further details please contact mediarelations@volition.com.
About Volition
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition's website volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition +44 (0)7557 774620 | Scott Powell, Volition investorrelations@volition.com +1 (646) 650 1351 |
Jen Lewis, Pegasus +44 (0)7809 867943 | Joseph Green, Edison Advisors +1 (646) 653 7030 |
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing of completion of studies and the release of data, the effectiveness of Volition's blood-based diagnostic and prognostic tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content to download multimedia:http://www.prnewswire.com/news-releases/national-taiwan-university-hospital-presents-data-on-nuq-assay-performance-at-the-world-conference-on-lung-cancer-301217090.html
SOURCE VolitionRx Ltd
FAQ
What are the key findings from VolitionRx's presentation at WCLC?
What is the significance of the study conducted at National Taiwan University Hospital?
When will the complete results of the study be published?
How does VolitionRx's technology improve lung cancer diagnosis?
What is VolitionRx's stock symbol and market relevance?
